Clinical trial
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
NCT01830985
Study timeline
Study start (unknown)2013-04-01Date precision: month
Registry last updated2015-11-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Rheumatoid Arthritisunresolved
Interventions
VX-509DRUG
Sponsors & collaborators
Vertex Pharmaceuticals Incorporatedlead sponsor
Mapped research locations
San AntonioTexas, United States1RochesterNew York, United States1CharlestonSouth Carolina, United States1MemphisTennessee, United States1SpokaneWashington, United States1Fort LauderdaleFlorida, United States1DecaturGeorgia, United States1West Palm BeachFlorida, United States1LincolnNebraska, United States1GreensboroNorth Carolina, United States1PretoriaSouth Africa1TallinnEstonia1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01830985 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.